TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25175495
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg THC + 40 mg MPH
Study: 20973909
Drug: Operative time,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Operative time, estimated blood loss (EBL), postoperative stay, analgesics use, changes in creatinine and haemoglobin levels, postoperative SF-36 scores
Study: 19884550
Drug: Epoetin alfa
Normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epoetin alfa (10,000 U SC three times weekly if baseline Hb < 12.5 g/dL; 4,000 U SC three times weekly if baseline Hb >= 12.5 g/dL)
Study: 17132120
Drug: Manual therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manual therapy (six sessions)
Study: 16329348
Drug: Fexofenadine (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fexofenadine (120 mg/d for 10 days)
Study: 16329348
Drug: Fluticasone (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluticasone (200 mcg/d for 10 days)
Study: 11504959
Drug: IDV +
Normalized name: Indinavir
DrugBank: Indinavir (DB00224)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IDV + ddI + d4T + hydroxyurea (HU) (600 mg twice daily)
Study: 20096432
Drug: Ghrelin (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ghrelin (3 microg/kg) administered intravenously twice daily for 10 days
Study: 10671656
Drug: Adjuvant radiation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant radiation therapy
Study: 7601014
Drug: Spirapril ≥
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spirapril ≥ 6 mg once daily
Study: 7601014
Drug: Spirapril (monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spirapril (monotherapy or in combination with hydrochlorothiazide)
Study: 28407247
Drug: Hormonal therapy
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hormonal therapy (NHT) for RS < 11
Study: 28407247
Drug: Hormonal therapy
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hormonal therapy (NHT) for RS 11-25
Study: 28407247
Drug: Chemotherapy (NCT)
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (NCT) for RS 11-25
Study: 28407247
Drug: Chemotherapy (NCT)
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (NCT) for RS > 25
Study: 11426667
Drug: Intravenous treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous treatment with folate (1.1 mg), cobalamin (1.0 mg), and pyridoxal phosphate (5.0 mg), administered twice weekly (group 2)
Study: 11426667
Drug: Intravenous treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous treatment with folate (1.1 mg), cobalamin (1.0 mg), and pyridoxal phosphate (5.0 mg), administered thrice weekly (group 3)
Study: 11426667
Drug: Intravenous treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous treatment with folate (1.1 mg), cobalamin (1.0 mg), and pyridoxal phosphate (5.0 mg), administered once weekly (group 1)
Study: 3081599
Drug: Cromolyn (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cromolyn (20 mg)
Study: 2879970
Drug: Chlorproguanil 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorproguanil 20 mg weekly
Study: 26688437
Drug: Structural group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Structural group therapy
Study: 23457678
Drug: Inhaled menthol
Normalized name: menthol Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled menthol
Study: 11587994
Drug: Sham inhalation
Normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham inhalation
Study: 9031393
Drug: Quinine 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quinine 600 mg tid for 5 days + Tetracycline 250 mg qid for 7 days (Q5T7; group A)
Study: 9031393
Drug: Quinine 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quinine 600 mg tid for 7 days + Tetracycline 250 mg qid for 7 days (Q7T7; group B)
Study: 1688971
Drug: Intravenous dibutyryl
Normalized name: Dibutyl Phthalate
DrugBank: Dibutylphthalate (DB13716)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous dibutyryl cyclic AMP (DBcyclicAMP)
Study: 11426360
Drug: Intravenous dobutamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous dobutamine
Study: 28722627
Drug: Intermittent preventive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent preventive treatment with sulfadoxine‐pyrimethamine (IPTp‐SP) alone without additional screening by CHWs.
Study: 12605289
Drug: Citalopram (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citalopram (20 mg daily for 6 days)
Study: 12605289
Drug: Reboxetine (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reboxetine (8 mg daily for 6 days)
Study: 2757957
Drug: Topical psoralen
Normalized name: Psoralen
DrugBank: Psoralen (DB18665)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical psoralen photochemotherapy (topical PUVA)
Study: 619946
Drug: Suxamethonium (0.08
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suxamethonium (0.08 mg/kg)
Study: 619946
Drug: Control period
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control period (before drug administration)
Study: 30509312
Drug: Atezolizumab (anti-PD-L1)
Normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Atezolizumab (anti-PD-L1) plus chemotherapy
Study: 25899314
Drug: Diclofenac (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diclofenac (100 mg preoperative dose)
Study: 23878845
Drug: 2% chlorhexidine
Normalized name: CHLORHEXIDINE GLUCONATE 1.2 [iU] in 1 mL BUCCAL MOUTHWASH [0.12% Chlorhexidine Gluconate Oral Rinse]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% chlorhexidine solution (Concepsis, Ultradent) applied on the etched dentin for 60 seconds
Study: 12892690
Drug: Large pad
Normalized name: ISOPROPYL ALCOHOL 0.7 mL in 1 mL TOPICAL CLOTH [Alcohol Prep Pad Large Pad]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Large pad loss (42 g)
Study: 12892690
Drug: Small pad
Normalized name: smallpox vaccine live, New York City Board of Health vaccinia strain Injectable Solution [ACAM2000]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Small pad loss (7 g)
Study: 10481920
Drug: 900 mg
Normalized name: diosmin 900 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 900 mg Kwai garlic
Study: 10252496
Drug: Linear self-instructional
Normalized name: Aspalathus linearis leaf extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Linear self-instructional program on the nature and treatment of IHD
Study: 27696703
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care (could include ambulatory physical therapy)
Study: 19551762
Drug: Topiramate (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topiramate (300 mg/day) and Aripiprazole (30 mg/day)
Study: 17580388
Drug: Steroids according
Normalized name: clozapine
DrugBank: Clozapine (DB00363)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Steroids according to ISKDC regimen
Study: 10677093
Drug: Beta carotene,
Normalized name: Beta Carotene, 15 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta carotene, 50 mg, on alternate days
Study: 2184694
Drug: nalbuphine 0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: nalbuphine 0.1 mg/kg
Study: 8442961
Drug: droperidol 0.025
Approvals — FDA: no, EMA: no, PMDA: no
Description: droperidol 0.025 mg/kg
Study: 3715980
Drug: Isoniazid daily
Normalized name: Isoniazid
DrugBank: Isoniazid (DB00951)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isoniazid daily at 20 mg/kg
Study: 3715980
Drug: Isoniazid daily
Normalized name: Isoniazid
DrugBank: Isoniazid (DB00951)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isoniazid daily at 12 mg/kg
Study: 3715980
Drug: Rifampicin administered
Normalized name: rifampicin
DrugBank: Rifampin (DB01045)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rifampicin administered twice a week
Study: 3715980
Drug: All regimens
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: All regimens (including steroids)
Study: 30064406
Drug: Single-agent chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-agent chemotherapy combined with bevacizumab
Study: 23285702
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg cefuroxime axetil film-coated tablets (test product)
Study: 20630128
Drug: High serum
Approvals — FDA: no, EMA: no, PMDA: no
Description: High serum alkaline phosphatase (>= 97 IU/l)
Study: 20630128
Drug: Low serum
Normalized name: ZINC OXIDE 20 g in 100 mL TOPICAL CREAM [Sunceutical SPF 50 Mineral Glow Serum]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low serum alkaline phosphatase (< 97 IU/l)
Study: 10465076
Drug: Vitamin A
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin A supplementation (5000 IU retinyl palmitate and 30 mg beta-carotene during the third trimester, 200000 IU retinyl palmitate at delivery)
Study: 2653391
Drug: Flosequinan 100
Normalized name: flosequinan 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flosequinan 100 mg daily
Study: 9579492
Drug: Meperidine (target
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meperidine (target plasma concentration of 1.2 microg/ml)
Study: 9579492
Drug: Alfentanil (target
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alfentanil (target plasma concentration of 0.2 microg/ml)
Study: 7659765
Drug: Active TRP
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active TRP depletion followed by intranasal cocaine
Study: 7659765
Drug: Sham depletion
Normalized name: Allogeneic thymocyte-depleted thymus tissue-agdc
DrugBank: Allogeneic processed thymus tissue (DB16736)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham depletion followed by intranasal cocaine
Study: 6251114
Drug: FK 33824
Normalized name: FK-960
DrugBank: FK-960 (DB06465)
Approvals — FDA: no, EMA: no, PMDA: no
Description: FK 33824 (0.5 mg i.m.)
Study: 23373103
Drug: Intravenous furosemide
Normalized name: Furosemide
DrugBank: Furosemide (DB00695)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous furosemide at a dose equivalent to the daily oral dose
Study: 9706945
Drug: Transdermal nicotine
Normalized name: nicotine Transdermal System
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal nicotine system (TD-NICO) 21 mg/d for at least 10 h before anesthesia
Study: 9706945
Drug: Abstinent group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abstinent group (ABST) with placebo transdermal system
Study: 9706945
Drug: Transdermal nicotine
Normalized name: nicotine Transdermal System
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal nicotine system (TD-NICO)
Study: 7621689
Drug: Soft jelly
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soft jelly capsules containing nonoxynol
Study: 19244932
Drug: Placebo with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo with glucose polymer (252 g) for 5 days (PL‐GP)
Study: 19244932
Drug: Creatine (21
Approvals — FDA: no, EMA: no, PMDA: no
Description: Creatine (21 g) with glucose polymer (252 g) for 5 days (CR‐GP)
Study: 12466506
Drug: Rate-control therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rate-control therapy
Study: 12950123
Drug: Oral tegafur-uracil
Normalized name: tegafur / uracil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tegafur-uracil plus folinic acid (UFT group)
Study: 12950123
Drug: Intravenous 5-fluorouracil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous 5-fluorouracil plus folinic acid (5-FU group)
Study: 10904241
Drug: Telmisartan 40-120
Normalized name: telmisartan 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telmisartan 40-120 mg
Study: 8738587
Drug: Standard heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard heparin (UF heparin)
Study: 1548522
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy (n = 160)
Study: 25015027
Drug: MPH-LA 60
Normalized name: MPH
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: MPH-LA 60 mg/day
Study: 25015027
Drug: MPH-LA 80
Normalized name: MPH
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: MPH-LA 80 mg/day
Study: 23129008
Drug: Intracoronary infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intracoronary infusion of 150 × 10^6 BMCs
Study: 23129008
Drug: Intracoronary infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intracoronary infusion of BMCs at day 3
Study: 23129008
Drug: Intracoronary infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intracoronary infusion of BMCs at day 7
Study: 23129008
Drug: Intracoronary infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intracoronary infusion of BMCs
Study: 15928685
Drug: Fortified pasteurised
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fortified pasteurised milk (200 µg folic acid)
Study: 12721666
Drug: Celecoxib (maximum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celecoxib (maximum single dose 200 mg, cumulative daily dose 350 mg)
Study: 29745006
Drug: 30 min
Normalized name: Goddess Garden SPF 30 Mineral Sunscreen
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 min of intradialytic exercise (IDEX) in the first hour of treatment
Study: 29745006
Drug: 30 min
Normalized name: Goddess Garden SPF 30 Mineral Sunscreen
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 min of intradialytic exercise (IDEX) in the third hour of treatment
Study: 26892910
Drug: Refusal of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Refusal of Nicotine Replacement Therapy (NRT)
Study: 20851230
Drug: 0.02 mg
Normalized name: escin 0.02 MG/MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.02 mg ethinylestradiol and 2 mg chlormadinone acetate (CMA)
Study: 31605392
Drug: Ropivacaine 0.2%
Normalized name: ROPivacaine 0.2% injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine 0.2% 10 mL
Study: 7617541
Drug: Multiple-dose terodiline
Normalized name: terodiline
DrugBank: Terodiline (DB13725)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple-dose terodiline (12.5 mg b.i.d. for 14 days)
Study: 7617541
Drug: Multiple-dose terodiline
Normalized name: terodiline
DrugBank: Terodiline (DB13725)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple-dose terodiline (25 mg b.i.d. for 14 days)
Study: 7617541
Drug: Overall terodiline
Normalized name: terodiline
DrugBank: Terodiline (DB13725)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall terodiline treatment
Study: 6327190
Drug: Veralipride 100
Normalized name: veralipride 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Veralipride 100 mg per day for 20 days
Study: 6327190
Drug: Conjugated oestrogens
Normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conjugated oestrogens 1.25 mg per day for 20 days
Study: 28678622
Drug: Placebo solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo solution (RP)
Study: 22855310
Drug: Non-BIOPATCH (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-BIOPATCH (no patch applied)
Study: 19898245
Drug: Fluoxetine-clonazepam cotherapy
Normalized name: Clonazepam
DrugBank: Clonazepam (DB01068)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluoxetine-clonazepam cotherapy
Study: 19723786
Drug: Fluoxetine monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine monotherapy
Study: 12118025
Drug: Doxorubicin and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxorubicin and paclitaxel (AT) regimen (doxorubicin 60 mg/m² IV bolus + paclitaxel 175 mg/m² 3-hour infusion)
Study: 8126635
Drug: Ceftriaxone (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftriaxone (1 g i.v. single dose)
Study: 8126635
Drug: Cefoxitin (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefoxitin (1 g i.v. three doses)
Study: 16549839
Drug: Bevacizumab infusion
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab infusion (VEGF antibody blockade)
Study: 3884806
Drug: Piroxicam, 20
Normalized name: Piroxicam, 20 mg oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piroxicam, 20 mg OD
Study: 3884806
Drug: Enteric coated
Normalized name: Mesasal Enteric Coated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enteric coated acetylsalicylic acid (EC ASA), 3.9‐5.2 g daily in divided doses
Study: 29369834
Drug: Oral 3%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral 3% hypertonic saline (HTS)
Study: 26628478
Drug: Lapatinib 1,250mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lapatinib 1,250mg daily plus CapeOx
Study: 18818415
Drug: Pioglitazone (PIO)
DrugBank: Pioglitazone (DB01132)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pioglitazone (PIO) therapy
Study: 14690186
Drug: Continuous intravenous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous intravenous SonoVue contrast echocardiography
Study: 26194850
Drug: Lipid-Based Nutrient
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lipid-Based Nutrient Supplements (LNS)
Study: 22978102
Drug: Diacerein Capsule
DrugBank: Diacerein (DB11994)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diacerein Capsule (DC)
Study: 22978102
Drug: Qianggu Granule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Qianggu Granule (QGG) + Diacerein Capsule (DC)
Study: 10657819
Drug: Exercise group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise group (10 tuck jumps 3 times weekly, jumping, hopping, and skipping incorporated into twice weekly physical education classes)
Study: 21808985
Drug: Intravenous thrombolysis
Normalized name: thrombocytin
DrugBank: Serotonin (DB08839)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous thrombolysis with alteplase (0.9 mg/kg)
Study: 15620935
Drug: Collagen-gentamicin (260
Approvals — FDA: no, EMA: no, PMDA: no
Description: Collagen-gentamicin (260 mg gentamicin) sponges applied within the sternotomy before wound closure
Study: 17931240
Drug: Intravenous isoxazolyl
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous isoxazolyl penicillin alone
Study: 17931240
Drug: Collagen-gentamicin (260
Approvals — FDA: no, EMA: no, PMDA: no
Description: Collagen-gentamicin (260 mg gentamicin) sponges
Study: 15925031
Drug: Clonidine (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonidine (0.3 mg/day)
Study: 15536640
Drug: Active placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active placebo (loratadine 10 mg/day)
Study: 11907500
Drug: Finasteride, 1
Normalized name: Finasteride, 1 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Finasteride, 1 mg/d
Study: 2093381
Drug: Trimetazidine (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimetazidine (60 mg per day)
Study: 2093381
Drug: Nifedipine (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine (40 mg per day)
Study: 28187751
Drug: simeprevir 75
Normalized name: Simeprevir
DrugBank: Simeprevir (DB06290)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: simeprevir 75 mg once daily + TMC647055 450 mg once daily/ritonavir 30 mg once daily + ribavirin 1000-1200 mg/day (Panel 1)
Study: 28187751
Drug: simeprevir 75
Normalized name: Simeprevir
DrugBank: Simeprevir (DB06290)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: simeprevir 75 mg once daily + TMC647055 450 mg once daily/ritonavir 30 mg once daily + ribavirin 1000-1200 mg/day (Panel 2-Arm 1)
Study: 28187751
Drug: simeprevir 75
Normalized name: Simeprevir
DrugBank: Simeprevir (DB06290)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: simeprevir 75 mg + TMC647055 450 mg/ritonavir 30 mg without ribavirin (Panel 2-Arm 2)
Study: 28187751
Drug: simeprevir 75
Normalized name: Simeprevir
DrugBank: Simeprevir (DB06290)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: simeprevir 75 mg + TMC647055 450 mg/ritonavir 30 mg + JNJ-56914845 30 mg once daily (Panel 4-Arm 1)
Study: 28187751
Drug: simeprevir 75
Normalized name: Simeprevir
DrugBank: Simeprevir (DB06290)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: simeprevir 75 mg + TMC647055 450 mg/ritonavir 30 mg + JNJ-56914845 60 mg once daily (Panel 4-Arm 2)
Study: 3060151
Drug: Metoclopramide (high-dose)
DrugBank: Metoclopramide (DB01233)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Metoclopramide (high-dose)
Study: 31197894
Drug: Daylight PDT
Normalized name: calcium carbonate
DrugBank: Calcium carbonate (DB06724)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Daylight PDT with curettage (standard treatment)
Study: 26004075
Drug: Topical citicoline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical citicoline (OMK1®, Omikron Italia, 3 drops/day) over a 4-month period
Study: 28239491
Drug: Beta-blocker monotherapy
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-blocker monotherapy
Study: 23084029
Drug: Combination Z
Normalized name: Z-160
DrugBank: Z-160 (DB12743)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination Z (oxygenated alcoholic beverage and oxygenated water)
Study: 23084029
Drug: Combination X
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination X (normal alcoholic beverage and normal water)
Study: 23084029
Drug: Combination Y
Normalized name: Neuropeptide Y
DrugBank: Neuropeptide Y (DB11788)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination Y (oxygenated alcoholic beverage and normal water)
Study: 21784297
Drug: Medication switch
Normalized name: witch hazel Medicated Pad
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication switch (SSRI or venlafaxine) with cognitive-behavioral therapy
Study: 22354934
Drug: Heparin plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin plus a GPI
Study: 21907540
Drug: Fluoxetine (SSRI)
DrugBank: Fluoxetine (DB00472)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluoxetine (SSRI)
Study: 8342757
Drug: Intermittent bolus
Normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent bolus injection (Group B, n = 10)
Study: 8342757
Drug: Patient controlled
Normalized name: PATIENT CONTROLLED ANALGESIA VIAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient controlled administration with continuous infusion (Group P, n = 10)
Study: 1936347
Drug: Ultrasonic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasonic therapy
Study: 9184268
Drug: Muscle relaxant
Normalized name: MUSCLE RELAXANTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Muscle relaxant drugs
Study: 20441723
Drug: Citalopram (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citalopram (20 mg to 50 mg/d)